- Latest available (Revised)
- Original (As made)
The Veterinary Medicines (Amendment etc.) Regulations 2024
You are here:
- UK Statutory Instruments
- 2024 No. 567
- PART 3
- Regulation 29
What Version
Opening Options
More Resources
Status:
This is the original version (as it was originally made). This item of legislation is currently only available in its original format.
Amendment to paragraph 3
This section has no associated Explanatory Memorandum
29. For paragraph 3 (summary of product characteristics) substitute—
“Summary of product characteristics
3.—(1) Subject to sub-paragraph (2), the summary of product characteristics required under paragraph 2(2)(h) must include the following information in the order indicated below—
| 1. | Name of the veterinary medicinal product, followed by its strength and pharmaceutical form. | |
| 2. | Qualitative and quantitative composition of the active substances and qualitative composition of excipients and other constituents stating their common name or their chemical description and their quantitative composition, if that information is essential for proper administration of the veterinary medicinal product. | |
| 3. | Clinical information as regards— | |
| 3.1 | target species; | |
| 3.2 | indications for use for each target species; | |
| 3.3 | contra-indications; | |
| 3.4 | special warnings; | |
| 3.5 | special precautions for use, including in particular special precautions for safe use in the target species, special precautions to be taken by the person administering the veterinary medicinal product to the animals and special precautions for the protection of the environment; | |
| 3.6 | frequency and seriousness of adverse events; | |
| 3.7 | use during pregnancy, lactation or lay; | |
| 3.8 | interaction with other medicinal products and other forms of interaction; | |
| 3.9 | administration route and dosage; | |
| 3.10 | symptoms of overdose and, where applicable, emergency procedures and antidotes in the event of overdose; | |
| 3.11 | special restrictions for use; | |
| 3.12 | special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance; | |
| 3.13 | if applicable, withdrawal periods, even if such periods are zero. | |
| 4. | Pharmacological information as regards— | |
| 4.1 | the ATCvet Code; | |
| 4.2 | pharmacodynamics; | |
| 4.3 | pharmacokinetics. | |
| 5. | Pharmaceutical particulars as regards— | |
| 5.1 | major incompatibilities; | |
| 5.2 | shelf-life, where applicable after reconstitution of the medicinal product or after the immediate packaging has been opened for the first time; | |
| 5.3 | special precautions for storage; | |
| 5.4 | nature and composition of immediate packaging; | |
| 5.5 | requirement to use take-back schemes for veterinary medicinal products for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products and, if appropriate, additional precautions regarding hazardous waste disposal of unused veterinary medicinal products or waste materials derived from the use of such products. | |
| 6. | Name of the holder of the marketing authorisation. | |
| 7. | Marketing authorisation number or numbers. | |
| 8. | Date of the first marketing authorisation. | |
| 9. | Date of the last revision of the summary of product characteristics. | |
| 10. | If applicable, the statement— | |
| 10.1 | “marketing authorisation granted for a limited market and therefore assessment based on customised requirements for documentation”; or | |
| 10.2 | “marketing authorisation in exceptional circumstances and therefore assessment based on customised requirements for documentation”. | |
| 11. | Information on the take-back schemes referred to in point 5.5 applicable to the veterinary medicinal product concerned. | |
| 12. | Classification of the veterinary medicinal product. | |
(2) In the case of an immunological veterinary medicinal product or a biological veterinary medicinal product that is not immunological, in place of the information at points 4, 4.1, 4.2 and 4.3, the summary of product characteristics must include immunological information.”.
Options/Help
Print Options
PrintThe Whole Instrument
PrintThe Whole Part
PrintThis Section only
You have chosen to open The Whole Instrument
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
You have chosen to open The Whole Instrument as a PDF
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
You have chosen to open The Whole Instrument without Schedules
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
You have chosen to open The Whole Instrument without Schedules as a PDF
The Whole Instrument without Schedules you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
You have chosen to open the Whole Instrument
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Legislation is available in different versions:
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Opening Options
Different options to open legislation in order to view more content on screen at once
Explanatory Memorandum
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
More Resources
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as enacted version that was used for the print copy
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- correction slips
- links to related legislation and further information resources
More Resources
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
- the original print PDF of the as made version that was used for the print copy
- correction slips
Click 'View More' or select 'More Resources' tab for additional information including:
- lists of changes made by and/or affecting this legislation item
- confers power and blanket amendment details
- all formats of all associated documents
- links to related legislation and further information resources
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.